Francisco Sanchez-Vega is an Assistant Attending Computational Oncologist in the Colorectal Cancer Service of the Department of Surgery with a secondary appointment in the Computational Oncology Service. His research focuses on translational applications of machine learning, statistical modeling and computational methods to the field of cancer genomics and precision oncology. Dr. Sanchez-Vega’s doctoral research work addressed the challenge of learning graphical models to efficiently describe high-dimensional, multivariate probability distributions within the context of small-sample regimes. During his postdoctoral experience at the National Human Genome Research Institute, he investigated patterns of aberrant DNA methylation in cancer and identified novel epigenetic biomarkers that could be used for early detection through non-invasive screening tests. Since his arrival at MSK in 2015, he has worked in a wide variety of translational genomic projects. Notable examples include the analysis of molecular determinants of response to anti-HER2 targeted therapies in patients with ERBB2 positive esophagogastric adenocarcinomas, understanding the interplay between mutational burden and response to immune checkpoint inhibitors in lung adenocarcinoma and characterizing the genomic bases of organ-specific metastasis. Dr. Sanchez-Vega was also actively involved and played leadership roles in several of the final marker papers from The Cancer Genome Atlas (TCGA) and the TCGA Pan-Cancer Atlas initiative. In April 2019, he joined the Colorectal Cancer Research Center at MSK, where he leads several research projects that aim to characterize the genomic landscape of somatic and transcriptomic alterations in colorectal cancer, including both patients with early and advanced metastatic disease. His current work also involves the identification of genomic determinants of response to total neoadjuvant therapy in patients with locally advanced rectal cancer, as well as novel applications of circulating tumor DNA analyses for detection of minimal residual disease.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Francisco Sanchez-Vega discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.